The CD70-targeting CTX131 heads for the scrapheap.
ApexOnco Front Page
Recent articles
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.